In last trading session, TransCode Therapeutics Inc (NASDAQ:RNAZ) saw 1.06 million shares changing hands with its beta currently measuring 0.63. Company’s recent per share price level of $0.68 trading at -$0.06 or -8.11% at ring of the bell on the day assigns it a market valuation of $11.73M. That closing price of RNAZ’s stock is at a discount of -3017.65% from its 52-week high price of $21.20 and is indicating a premium of 67.65% from its 52-week low price of $0.22. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.22 million shares which gives us an average trading volume of 2.14 million if we extend that period to 3-months.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Upright in the red during last session for losing -8.11%, in the last five days RNAZ remained trading in the green while hitting it’s week-highest on Friday, 10/11/24 when the stock touched $0.68 price level, adding 15.0% to its value on the day. TransCode Therapeutics Inc’s shares saw a change of -89.70% in year-to-date performance and have moved 25.55% in past 5-day. TransCode Therapeutics Inc (NASDAQ:RNAZ) showed a performance of 134.17% in past 30-days. Number of shares sold short was 1.38 million shares which calculate 0.45 days to cover the short interests.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Statistics highlight that TransCode Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 35.41% of value to its shares in past 6 months, showing an annual growth rate of 98.01% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -28.81% during past 5 years.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
Insiders are in possession of 0.03% of company’s total shares while institution are holding 11.46 percent of that, with stock having share float percentage of 11.47%. Investors also watch the number of corporate investors in a company very closely, which is 11.46% institutions for TransCode Therapeutics Inc that are currently holding shares of the company.
